Adjusted fiscal 2009 guidance excludes $7-8 million, or approximately $0.17-$0.20 per share, of costs to restructure other areas of Haemonetics' business, including manufacturing, quality, R&D, and ...
BOSTON, June 3, 2020 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative hematology solutions to drive better patient outcomes, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results